Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

LYNK Pharmaceuticals / Equity Capital Markets

<ul>
<li>Lynk Pharmaceuticals, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC and CCBI are the joint sponsors.</li>
<li>In this note, we look at the company’s two late-stage core products and one pre-clinical key product.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Lynk Pharmaceuticals, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CITIC and CCBI are the joint sponsors.
In this note, we look at the company’s two late-stage core products and one pre-clinical key product.
We also look at the company’s pre-IPO investors and management team.


Lynk (凌科药业) Pre-IPO: Reality Checks for the JAK Specialist

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, after a stellar listing for Montage, other listings during the week didn't do much.</li>
<li>On the placement front, we had a look at a few of the upcomng lockup expiries.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, after a stellar listing for Montage, other listings during the week didn't do much.
On the placement front, we had a look at a few of the upcomng lockup expiries.


Aequitas ECM Weekly (16 February 2026)- Montage, Axera, Wuxi Lead, Woer, Top Toy, Anker, PhonePe

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

LYNK Pharmaceuticals (LYNK HK)

Lynk (凌科药业) Pre-IPO: Reality Checks for the JAK Specialist

China's Lynk Pharmaceuticals seeks to raise $100 million through Hong Kong listing. In this note, we look at its two JAK products LNK01001 and...

Ke Yan, CFA, FRM

Aequitas ECM Weekly (16 February 2026)- Montage, Axera, Wuxi Lead, Woer, Top Toy, Anker, PhonePe

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Lynk (凌科药业) Pre-IPO: Reality Checks for the JAK Specialist

​China's Lynk Pharmaceuticals seeks to raise $100 million through Hong Kong listing. In this note, we look at its two JAK products LNK01001 and...

Ke Yan, CFA, FRM

Aequitas ECM Weekly (16 February 2026)- Montage, Axera, Wuxi Lead, Woer, Top Toy, Anker, PhonePe

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

China's Lynk Pharmaceuticals seeks to raise $100 million through Hong Kong listing. In this note, we look at its two JAK products LNK01001 and...